Reflex sympathetic dystrophy syndrome and neuromediators.
Concepts related to the pathophysiology of reflex sympathetic dystrophy syndrome (RSDS) are changing. Although sympathetic influences are still viewed as the most likely mechanism underlying the development and/or perpetuation of RSDS, these influences are no longer ascribed to an increase in sympathetic tone. Rather, the most likely mechanism may be increased sensitivity to catecholamines due to sympathetic denervation with an increase in the number and/or sensitivity of peripheral axonal adrenoceptors. Several other pathophysiological mechanisms have been suggested, including neurogenic inflammation with the release of neuropeptides by primary nociceptive afferents and sympathetic efferents. These neuromediators, particularly substance P, calcitonin gene-related peptide, and neuropeptide Y (NPY), may play a pivotal role in the genesis of pain in RSDS. They induce an inflammatory response (cutaneous erythema and edema) and lower the pain threshold. Neurogenic inflammation at the site of the lesion with neuromediator accumulation or depletion probably contributes to the pathophysiology of RSDS. However, no single neuromediator has been proved responsible, and other hypotheses continue to arouse interest.
Pham
Thao
T
Rheumatology department of Professeur Lafforgue, Hôpital de la Conception (4e sud), boulevard Baille, 13005 Marseille, France. thao.pham@ap-hm.fr
Lafforgue
Pierre
P
D015740:Calcitonin Gene-Related Peptide / Q000502:physiology; D006801:Humans; D020078:Neurogenic Inflammation / Q000503:physiopathology; D009478:Neuropeptide Y / Q000502:physiology; D009479:Neuropeptides / Q000502:physiology*; D010146:Pain / Q000503:physiopathology; D012019:Reflex Sympathetic Dystrophy / Q000209:etiology / Q000503:physiopathology*; D013373:Substance P / Q000502:physiology; D013564:Sympathetic Nervous System / Q000503:physiopathology; D013577:Syndrome
D009478:Neuropeptide Y; D009479:Neuropeptides; D013373:Substance P; D015740:Calcitonin Gene-Related Peptide